Guardant Health (GH) is up 4.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to continued bullish sentiment after Guardant Health posted strong second-quarter results, raised its 2026 revenue outlook, and highlighted rapid adoption of its Shield colorectal cancer screening test. Recent reimbursement and guideline wins, along with follow-on analyst price-target increases, likely added support.

Details:

  • Guardant Health reported second-quarter 2026 revenue of $335.0 million, up 44% year over year, and lifted full-year revenue guidance to $1.34 billion to $1.36 billion.
  • Screening revenue grew more than 250%, helped by Shield test volume rising to about 66,000 in the quarter, which signaled accelerating adoption in blood-based colorectal cancer screening.
  • The company said UnitedHealth Group now covers Shield for eligible members, expanding access through a major commercial insurer and strengthening the product’s reimbursement profile.
  • Shield was also added to updated American Cancer Society screening guidelines earlier this year, and several analysts raised their price targets after the earnings release, reinforcing positive expectations.

    • Sources:

    Guardant Health Investor Relations, Yahoo Finance, TipRanks

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $GH Insider Trading Activity

    GH Insider Trades

    $GH insiders have traded $GH stock on the open market 74 times in the past 6 months. Of those trades, 1 have been purchases and 73 have been sales.

    Here’s a breakdown of recent trading of $GH stock by insiders over the last 6 months:

    • AMIRALI TALASAZ (Co-Chief Executive Officer) has made 0 purchases and 19 sales selling 520,000 shares for an estimated $67,405,344.
    • CHRIS FREEMAN (Chief Commercial Officer) has made 0 purchases and 5 sales selling 88,011 shares for an estimated $13,682,471.
    • HELMY ELTOUKHY (Co-Chief Executive Officer) has made 0 purchases and 7 sales selling 100,000 shares for an estimated $12,629,968.
    • TERILYN J. MONROE (Chief People Officer) has made 0 purchases and 6 sales selling 50,132 shares for an estimated $8,000,367.
    • KUMUD KALIA (Chief Information Officer) has made 1 purchase buying 600 shares for an estimated $78,456 and 6 sales selling 49,618 shares for an estimated $5,067,010.
    • JOHN G. SAIA (Chief Legal Officer) has made 0 purchases and 5 sales selling 30,000 shares for an estimated $3,381,064.
    • IAN T CLARK has made 0 purchases and 3 sales selling 21,056 shares for an estimated $2,988,499.
    • MEGHAN V. JOYCE has made 0 purchases and 4 sales selling 10,000 shares for an estimated $1,269,808.
    • STEVE E. KROGNES sold 9,294 shares for an estimated $1,231,521
    • MEDINA MANUEL HIDALGO has made 0 purchases and 7 sales selling 5,250 shares for an estimated $662,122.
    • MICHAEL BRIAN BELL (Chief Financial Officer) has made 0 purchases and 2 sales selling 5,000 shares for an estimated $518,351.
    • MUSA TARIQ has made 0 purchases and 7 sales selling 2,879 shares for an estimated $359,712.
    • MYRTLE S POTTER sold 1,556 shares for an estimated $204,084
    See also  Forget Micron for a Minute: This Memory Competitor Just Crossed a Major Profitability Milestone

    To track insider transactions, check out Quiver Quantitative’s insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    EARLY ACCESS

    Receive GH Data Alerts

    Real-time alerts on filings, insider trades, and market signals — before everyone else.


    Get Alerts →

    $GH Hedge Fund Activity

    We have seen 349 institutional investors add shares of $GH stock to their portfolio, and 256 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • BLACKROCK, INC. removed 3,930,824 shares (-34.0%) from their portfolio in Q2 2026, for an estimated $589,741,524
    • BAILLIE GIFFORD & CO removed 2,605,899 shares (-53.3%) from their portfolio in Q2 2026, for an estimated $390,963,026
    • PIER 88 INVESTMENT PARTNERS LLC removed 2,050,800 shares (-99.7%) from their portfolio in Q2 2026, for an estimated $307,681,524
    • JANE STREET GROUP, LLC added 1,778,641 shares (+37031.9%) to their portfolio in Q2 2026, for an estimated $266,849,509
    • AMERIPRISE FINANCIAL INC added 1,736,011 shares (+122.7%) to their portfolio in Q2 2026, for an estimated $260,453,730
    • FMR LLC added 1,372,191 shares (+33.3%) to their portfolio in Q2 2026, for an estimated $205,869,815
    • WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 1,311,320 shares (+inf%) to their portfolio in Q2 2026, for an estimated $196,737,339

    To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $GH Price Targets

    Multiple analysts have issued price targets for $GH recently. We have seen 15 analysts offer price targets for $GH in the last 6 months, with a median target of $175.0.

    See also  Advanced Micro Devices vs. monday.com: Comparing Revenue Trends Between These High-Growth Tech Companies

    Here are some recent targets:

    • Shannon O’Callaghan from Morgan Stanley set a target price of $175.0 on 07/09/2026
    • Patrick Donnelly from Citigroup set a target price of $215.0 on 07/08/2026
    • Michael Ryskin from B of A Securities set a target price of $190.0 on 07/06/2026
    • Vijay Kumar from Evercore ISI Group set a target price of $200.0 on 07/06/2026
    • Eve Burstein from Bernstein set a target price of $200.0 on 07/02/2026
    • Mark Massaro from BTIG set a target price of $190.0 on 07/01/2026
    • Subbu Nambi from Guggenheim set a target price of $160.0 on 06/29/2026

    This article is not financial advice. See Quiver Quantitative’s disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.


    Source link